知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.032 seconds)

    ANTI-INTEGRIN ANTIBODIES AND USES THEREOF
    1.
    发明申请
    ANTI-INTEGRIN ANTIBODIES AND USES THEREOF 有权

    公开(公告)号：US20220195052A1

    公开(公告)日：2022-06-23

    申请号：US17599716

    申请日：2020-04-08

    Applicant: Biogen MA Inc.

    Inventor： Christilyn Graff ,  Christina Palmer ,  Brett Blakeley ,  Tracey Mullen ,  Agnes Gardet

    IPC: C07K16/28

    Abstract: Anti-integrin antibodies are disclosed. Also disclosed are methods of using the antibodies to treat or prevent disorders such as fibrotic diseases, cancer, ophthalmology disorders, and NAFLD. Further disclosed are methods of selecting an antibody that specifically binds to αvβ{umlaut over (í)}, or that binds to αvβ{umlaut over (í)} and αvβó, or that binds to one or more members of the RGD sub-family of integrins.

    Compositions Comprising Antibodies to Lingo or Fragments Thereof
    2.
    发明申请
    Compositions Comprising Antibodies to Lingo or Fragments Thereof 有权
    包含针对Lingo或其片段的抗体的组合物

    公开(公告)号：US20160368984A1

    公开(公告)日：2016-12-22

    申请号：US15165279

    申请日：2016-05-26

    Applicant: Biogen MA Inc.

    Inventor： Sha Mi ,  R. Blake Pepinsky ,  Christilyn Graff

    IPC: C07K16/28 ,  A61K45/06 ,  A61K47/48 ,  A61K39/395

    CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6849 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/01

    Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody

    Abstract translation: 内源性LINGO-1是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性LINGO-1功能的分子，如抗LINGO-1抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对LINGO-1特异性的抗体，以及使用这些抗体作为内源性LINGO-1功能的拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，包括对需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体

    SP35 Antibodies And Uses Thereof
    3.
    发明申请
    SP35 Antibodies And Uses Thereof 审中-公开
    SP35抗体及其用途

    公开(公告)号：US20150315273A1

    公开(公告)日：2015-11-05

    申请号：US14677521

    申请日：2015-04-02

    Applicant: Biogen MA Inc.

    Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber ,  Steven D. Miklasz ,  Christilyn Graff

    IPC: C07K16/28

    CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

    Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。

    ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
    4.
    发明申请
    ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES 有权

    公开(公告)号：US20220089745A1

    公开(公告)日：2022-03-24

    申请号：US17353402

    申请日：2021-06-21

    Applicant: Biogen MA Inc.

    Inventor： Bradley Pearse ,  Joe Salas ,  Robert Peters ,  Christilyn Graff

    IPC: C07K16/28 ,  C07K14/745 ,  C12N5/078 ,  C12N9/64 ,  G01N33/569

    Abstract: Antibodies and antigen-binding antibody fragments that bind to GPIIb/IIIa and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind GPIIb/IIIa on activated platelets while others do not show a preference for binding GPIIb/IIIa on resting versus activated platelets. Some of these antibodies and antibody fragments do not inhibit the interaction of GPIIb/IIIa with fibrinogen, while some others do. The disclosed antibodies do not induce platelet activation. Some of these antibodies and antigen-binding antibody fragments are useful in targeting therapeutic agents such as dotting factors to platelets while others are useful in reducing platelet aggregation and/or thrombus formation.

    SP35 Antibodies And Uses Thereof
    5.
    发明申请
    SP35 Antibodies And Uses Thereof 有权

    公开(公告)号：US20210395360A1

    公开(公告)日：2021-12-23

    申请号：US17217263

    申请日：2021-03-30

    Applicant: Biogen MA Inc.

    Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber Stark ,  Steven D. Miklasz ,  Christilyn Graff

    IPC: C07K16/28

    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

    SP35 Antibodies And Uses Thereof
    6.
    发明申请
    SP35 Antibodies And Uses Thereof 审中-公开
    SP35抗体及其用途

    公开(公告)号：US20170037126A1

    公开(公告)日：2017-02-09

    申请号：US15214818

    申请日：2016-07-20

    Applicant: Biogen MA Inc.

    Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber Stark ,  Steven D. Miklasz ,  Christilyn Graff

    IPC: C07K16/28

    CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

    Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。

    SP35 Antibodies And Uses Thereof
    7.
    发明申请
    SP35 Antibodies And Uses Thereof 审中-公开

    公开(公告)号：US20200317775A1

    公开(公告)日：2020-10-08

    申请号：US16789738

    申请日：2020-02-13

    Applicant: Biogen MA Inc.

    Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber Stark ,  Steven D. Miklasz ,  Christilyn Graff

    IPC: C07K16/28

    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

    SP35 Antibodies And Uses Thereof
    8.
    发明申请
    SP35 Antibodies And Uses Thereof 审中-公开

    公开(公告)号：US20190161546A1

    公开(公告)日：2019-05-30

    申请号：US16018819

    申请日：2018-06-26

    Applicant: Biogen MA Inc.

    Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber Stark ,  Steven D. Miklasz ,  Christilyn Graff

    IPC: C07K16/28

    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

Patent Agency Ranking